Navigating the New MedTech Playbook: How to Cross the Widening Early‑Stage Chasm
Venture Banking
Navigating the New MedTech Playbook is a series from Stifel Venture Banking’s Life Sciences & Healthcare team focused on the operational and financial realities shaping today’s medtech market. Drawing on conference takeaways, client work, investor conversations, and patterns observed across the life sciences ecosystem, the series explores the strategies, decisions, and market shifts shaping how medtech companies scale in a more disciplined capital environment.
Highlights:
- The Seed-to-Series A funding gap is widening as investors raise the bar on evidence and execution.
- Investors are evaluating regulatory, reimbursement, and commercialization plans earlier than ever.
- Commercial readiness is becoming as important as clinical readiness for companies approaching Series A.
- Scaling a sales team requires more than adding headcount, making onboarding and execution critical.
- The strongest companies reduce risk early and build a path to repeatable commercial scale.
MedTech fundraising has behaved like a barbell over the last two years.
On one end, early-stage companies with compelling technology and large market opportunities have continued to attract capital. On the other, later-stage businesses with strong clinical evidence, reimbursement clarity, and commercial traction have continued to secure growth financings and exits.
The biggest challenge now sits between Seed and Series A. According to PitchBook, MedTech VC deal value reached a three-year high of $16.1 billion in 2025, but activity became increasingly concentrated around later-stage companies nearing regulatory approval and payer coverage. Seed and early-stage rounds represented just 16.1% of total investment, well below the historical average of 29.1%.
The pattern stands in contrast with many other technology sectors, where AI-driven innovation continues to attract significant early-stage investment. In many ways, MedTech is behaving more like the biopharma market, where investors are also demanding greater clinical and operational validation before deploying capital.
For founders navigating the transition from Seed to Series A, the challenge is increasingly clear: they are often too mature to raise on vision alone, but not yet mature enough to meet today’s institutional proof thresholds. The industry’s most acute funding pressure now sits in this middle stage, where companies must demonstrate greater clinical, commercial, and operational maturity before they can access institutional capital.
The good news is that for companies with strong fundamentals and intentional execution, the current environment remains highly workable.
“The best seed-stage companies are not suddenly de-risked, but they are more disciplined. They know which risks matter most, how they plan to address them, and what proof points and relationships are needed before the next financing.”
In the first article of this series, we explored the operational and financial discipline increasingly separating successful MedTech companies from the rest of the market. This time, we’re focusing on what many investors now view as one of the most difficult transitions in MedTech: moving from early promise to institutional readiness.
Investors Are Underwriting More Than Clinical Risk
Medtech innovation has never been more compelling, particularly as AI expands what is possible. However, investors remain disciplined and are entering Series A conversations with a much broader set of questions and demanding better answers; technology and the clinical opportunity are now just the tip of the iceberg. As companies approach Series A, investors want to understand how a product will move through the healthcare system and ultimately become a scalable business. Who adopts it? Who pays for it? How does it fit into existing workflows? What evidence will support repeat utilization?
While these questions are not new, they are showing up earlier and more frequently in diligence conversations, reflecting a broader shift in how investors think about risk.
“On one end, investors are trying to de-risk as much as possible up front — market access and reimbursement clarity, validated pre-clinical or clinical data, and founding teams that can go the distance. On the other, they’re taking larger, riskier swings justified by the size of the long-term market opportunity. What’s thinning out is the middle: the moderately de-risked, moderately sized opportunity is the hardest profile to finance right now.”
Part of this shift reflects the realities of today’s financing environment. Investors have become more selective, financing cycles have lengthened, and companies are expected to operate longer between rounds. As a result, investors want greater confidence that key clinical, commercial, and operational risks can be managed before committing additional capital.
Commercialization Is Now Part of the Series A Story
As you approach Series A, investors increasingly want evidence that companies understand not only the technology itself but also the patient experience, clinical workflow, regulatory pathway, and commercial adoption dynamics. They are evaluating assumptions around reimbursement timing, physician adoption, hospital procurement, sales cycles, and economic buyers far earlier than they did several years ago. Seasoned investors also recognize that not asking these questions early on can come at a significant cost down the road.
“The reason is simple: getting regulatory or commercial strategy wrong can add years and tens of millions of dollars before a company reaches an exit or major value inflection point. Investors now understand that regulatory pathway, reimbursement, evidence generation, and go-to-market strategy are not downstream issues. They are core parts of the business model.”
Founders are now expected to think about what lies far beyond the clinical stage. Having an informed understanding of the regulatory roadmap and whether a product is likely to follow a 510(k), De Novo, or PMA pathway remains crucial. However, founders are also being asked to demonstrate earlier thinking around commercial launch strategy, target accounts, physician champions, reimbursement assumptions, and organizational buildout. It’s not just about the path to clinical evidence but also what evidence will be required to support wide-scale adoption to bring the product to market.
For AI-enabled businesses, the conversation increasingly centers on differentiation and defensibility: what is truly proprietary and how difficult your technology is to replicate. As AI tools become more accessible, investors are looking closely at what makes a company’s technology, data, workflow integration, or market position sticky and sustainable over time. Increasingly, investors want to see a differentiated intellectual property position, unique data assets, workflow integration advantages, or other barriers that become stronger as the business grows.
“When I’m evaluating a company, I focus on the ‘3 Ps’:
- Providers or Patients: Are there people willing and able to use the product? Is it solving a real need? Is it easy to use? Is it better than what’s already out there?
- Payers: Is there a reimbursement path already? If not, are there precedents that help determine the time and capital required to establish one?
- People: Do we have a management team with a track record of success against this risk profile or within this category?”
Once these core business assumptions are understood, the next question becomes how to finance the path forward. Capital planning is ultimately about determining the strategy that will enable you to achieve both near and long term milestones while maximizing efficiency and maintaining the pace of growth and execution. It is equally important to understand the full range of financing options available, including equity, grants, venture debt, and other funding mechanisms, and the role each can play within a broader capital strategy.
Transforming Strategy Into Execution: Scaling Beyond the First Reps
As companies plot the course to commercialization, it’s also important for founders and hiring leaders to maintain a long-term view and build a repeatable framework to scale the organization alongside the technology.
One pattern we see repeatedly is founders treating commercial expansion as a hiring challenge when it is really an operating challenge. The difficulty is rarely hiring the next three reps. It’s building a repeatable process that allows those reps to become productive quickly and consistently.
Going from two reps to five reps is not simply a matter of adding headcount. Going from five reps to ten introduces another set of challenges entirely. As organizations grow, onboarding, training, forecasting, management, and accountability become increasingly important.
In our experience, this is where many early commercialization plans break down. Initial customer traction can often be achieved through founder involvement and a handful of highly engaged champions. Scaling beyond that requires systems, processes, and onboarding that make success repeatable.
The companies that navigate this transition most effectively tend to think about commercialization well before they actively need a commercial team. By the time they’re hiring their first reps, they’ve already spent significant time validating adoption assumptions, reimbursement dynamics, purchasing workflows, and physician engagement strategies.
As a result, investors are increasingly evaluating commercial readiness through a more operational lens. How quickly do new hires become productive? Is there a repeatable sales process? Does the company have realistic assumptions around adoption timelines and sales cycles?
Being thoughtful about these types of questions and planning early on signals to investors that you understand not only the long-term goals but the work and the headcount required to get there.
The New Standard for Series A Readiness
Today’s MedTech financing environment looks very different than it did a few years ago. Capital is still available, but investors are applying a higher bar and spending more time evaluating how companies will navigate the path from innovation to commercial scale.
The companies navigating today’s Seed-to-Series A gap most successfully are not necessarily the ones with the most compelling technology. They are the ones demonstrating the clearest understanding of how that technology becomes a business.
The founders who navigate this transition most effectively treat commercialization, reimbursement, and operational scale as integral parts of the business long before they become urgent priorities. They recognize that many of the questions once reserved for later stages of growth are now showing up much earlier in the company lifecycle.
As the bar for institutional capital continues to rise, the companies that reduce uncertainty before they’re asked to will be the ones best positioned to reach the next stage of growth. Investors are still backing innovation, but increasingly, they’re rewarding founders who can pair a compelling vision with a credible plan for execution.
Stifel Venture Banking is a division of Stifel Bank, Member FDIC. For informational purposes only. Stifel Bank does not provide legal, tax, or other advice.
Written by
Related Insights
Other articles designed to help you along your financial journey.
